医学
氧气疗法
肺炎
内科学
2019年冠状病毒病(COVID-19)
回顾性队列研究
重症监护医学
疾病
传染病(医学专业)
作者
Peng Luo,Yuanfang Ding,Yuan He,Dafeng Chen,Qing‐Yu He,Zufeng Huang,Shian Huang,Wei Lei
出处
期刊:Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2022-03-04
卷期号:101 (9): e27759-e27759
被引量:4
标识
DOI:10.1097/md.0000000000027759
摘要
Abstract A global public health crisis caused by the 2019 novel coronavirus disease (COVID-19) leads to considerable morbidity and mortality, which bring great challenge to respiratory medicine. Hydrogen-oxygen therapy contributes to treat severe respiratory diseases and improve lung functions, yet there is no information to support the clinical use of this therapy in the COVID-19 pneumonia. A retrospective study of medical records was carried out in Shishou Hospital of Traditional Chinese Medicine in Hubei, China. COVID-19 patients (aged ≥ 30 years) admitted to the hospital from January 29 to March 20, 2020 were subjected to control group (n = 12) who received routine therapy and case group (n = 12) who received additional hydrogen-oxygen therapy. The clinical characteristics of COVID-19 patients were analyzed. The physiological and biochemical indexes, including immune inflammation indicators, electrolytes, myocardial enzyme profile, and functions of liver and kidney, were examined and investigated before and after hydrogen-oxygen therapy. The results showed significant decreases in the neutrophil percentage and the concentration and abnormal proportion of C-reactive protein in COVID-19 patients received additional hydrogen-oxygen therapy. This novel therapeutic may alleviate clinical symptoms of COVID-19 patients by suppressing inflammation responses.
科研通智能强力驱动
Strongly Powered by AbleSci AI